Workspace activity
Evidence updates
Recent updates from monitored sources, mapped to targets in the active landscape.
AI triageAI-assisted
1 update needs review now (new GWAS strengthens NaV1.7 genetics), 1 needs a source check (competitor pipeline mention), the rest can be monitored. Open questions are tagged on each signal.
6 signals shown. 3 affect targets in active landscape.
Genetic study AI · Review now
2026-05-04
New large-cohort GWAS for chronic neuropathic pain published; replicated signals at SCN9A and SCN11A loci
Illustrative scenario for the demo. Affected targets show updated qualitative confidence in the demo landscape.
Source: Illustrative GWAS for demo purposes
Affects:NaV1.7↑NaV1.9↑
View NaV1.7 deep dive Pipeline update AI · Source check
2026-04-22
Public VX-993 clinical update added to landscape monitoring
Specific update content to be inserted from public Vertex disclosure before launch. Treat as evidence that updates positioning, not a target-confidence verdict.
Source: Vertex public disclosure (verify content before launch)Verify content before launch
Affects:NaV1.8⇄
Regulatory milestone AI · Monitor
verify date
Latigo Biotherapeutics' LTG-001 receives FDA Fast Track designation as a NaV1.8 inhibitor
Active competitive program in NaV1.8 space.
Source: Latigo Biotherapeutics press release
Affects:NaV1.8⇄
Publication AI · Monitor
verify date
Eli Lilly publishes clinical proof-of-concept results for LY3526318, a TRPA1 antagonist
Proof-of-concept results published in peer-reviewed literature.
Source: Peer-reviewed publication (PubMed)
Affects:TRPA1↑
Class signal AI · Monitor
2026-04-15
Refractory chronic cough P2X3 program updates (gefapixant / camlipixant)
Class status update; pain-specific evidence remains limited.
Source: GSK and Merck disclosures
Affects:P2X3→
Safety review AI · Monitor
watchlist
Watchlist note: anti-NGF class safety signals remain under review
No new resolution data published. Watchlist tier maintained.
Source: Illustrative wording, anchored on real regulatory history
Affects:NGF→
This is the public-facing signal stream. Customer-internal signals (proprietary R&D, internal pipeline) would appear here in production with appropriate access controls.